<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brenda Vincenzi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Henderson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3025073"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Metabolic syndrome is a constellation of conditions including abdominal obesity, insulin resistance, dyslipidemia (elevated triglycerides levels and low high-density lipoprotein cholesterol), and hypertension. Patients with metabolic syndrome meeting formal criteria are at increased risk for premature cardiovascular disease, type 2 diabetes mellitus, and early death.</p><p>Metabolic syndrome represents a global epidemic. Severe mental illness, unhealthy lifestyles, and the use of antipsychotic medications all play an important role in increasing the risk of metabolic syndrome. Obesity, adipokines dysregulation, and inflammation are all recognized pathophysiologic mechanisms for metabolic syndrome.</p><p>This topic describes the diagnosis, epidemiology, pathogenesis, and clinical implications of metabolic syndrome. Modifiable risk factors for cardiovascular disease in patients with severe mental illness, including smoking cessation and individual metabolic abnormalities, are reviewed separately. Lifestyle interventions in patients with severe mental illness are also reviewed separately. (See  <a class="medical medical_review" href="/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness"</a> and  <a class="medical medical_review" href="/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness"</a>.)</p><p class="headingAnchor" id="H1500775932"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>Our approach to treating metabolic syndrome in patients with severe mental illness is described separately. (See  <a class="medical medical_review" href="/d/html/117204.html" rel="external">"Approach to managing increased risk for cardiovascular disease in patients with severe mental illness"</a>.)</p><p class="headingAnchor" id="H3025079"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Metabolic syndrome, also known as syndrome X, syndrome of chronic cardiovascular disease, or Reaven syndrome [<a href="#rid1">1</a>], is a constellation of conditions including abdominal obesity, insulin resistance, dyslipidemia (elevated triglycerides levels and low high-density lipoprotein cholesterol), and hypertension. Major clinical and research organizations have proposed specific criteria for diagnosing the syndrome. (See <a class="local">'Diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H3025085"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Metabolic syndrome has been recognized as a global problem of increasing prevalence (ie, an emerging epidemic) [<a href="#rid2">2</a>]. Its prevalence depends on the diagnostic criteria used and the ethnicity of the population studied [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2810810867"><span class="h2">Prevalence in general population</span><span class="headingEndMark"> — </span>Using criteria proposed by the American Heart Association [<a href="#rid4">4</a>], studies have estimated prevalence by ethnicity:</p><p class="bulletIndent1"><span class="glyph">●</span>Europeans – 14.4 percent in women; 18.4 percent of men [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>South Asian – 31.8 percent in women; 28.8 percent in men [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>African Caribbean – 23.4 percent in women; 15.5 percent in men [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Taiwan – 15.7 percent [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>United States – 23.4 percent (age-adjusted) in women; 24.0 percent (age-adjusted) in men [<a href="#rid7">7</a>]. However, among some ethnic groups, the difference in prevalence between female and male was greater:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>African Americans – Women approximately 57 percent, greater than that of men [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mexican Americans – Women approximately 26 percent, greater than that of men [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>East Asia – 2 to 18 percent in women; 8 to 13 percent in men [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>South America – Mean prevalence of 14 to 30 percent [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Australia – 20 to 30 percent [<a href="#rid9">9</a>].</p><p></p><p>There appear to be variations in metabolic syndrome rates across different psychotic disorders. Patients with schizoaffective disorders may be more prone to higher rates of metabolic abnormalities, such as dyslipidemia, glucose intolerance, diabetes, and obesity, compared with patients with schizophrenia or other nonaffective psychosis [<a href="#rid10">10-12</a>]. More research is needed into possible explanatory factors, including contributions of affective illness (eg, depressive symptoms leading to a sedentary and unhealthy lifestyle) and of various types of medication (antipsychotics, mood stabilizers, and antidepressants).</p><p class="headingAnchor" id="H147716478"><span class="h1">CONTRIBUTING FACTORS</span><span class="headingEndMark"> — </span>Multiple factors are believed to contribute to an increased risk of metabolic syndrome in patients with severe mental illness.</p><p class="headingAnchor" id="H3025091"><span class="h2">Mental disorders</span><span class="headingEndMark"> — </span>Some evidence of a relationship between severe mental illness and metabolic syndrome predates the era of antipsychotic medications, which began in the 1950s [<a href="#rid13">13</a>]. Antipsychotic medication-naïve patients with schizophrenia or schizoaffective disorders have been shown to present with hepatic insulin resistance compared with matched controls, suggesting a direct link between schizophrenia and insulin resistance independent from the use of antipsychotic medications [<a href="#rid14">14</a>].</p><p>With regard to other severe mental illnesses, some reports suggest that metabolic syndrome is present in 8 to 56 percent of patients suffering from bipolar disorder [<a href="#rid15">15</a>]. Depression accelerates cell aging; depressed individuals have a higher incidence of diseases of aging, such as cardiovascular and cerebrovascular diseases, metabolic syndrome, and dementia [<a href="#rid16">16</a>]. Although studies have identified significant linkages between depression and diabetes, findings are not consistent, but contradictory and confusing [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H3025097"><span class="h2">Lifestyle factors</span><span class="headingEndMark"> — </span>Although genetic factors might have a role in the physical health problems of patients with schizophrenia and severe mental illness, they also experience higher rates of comorbid physical health problems compared with the general population due to lifestyle and environmental factors, such as unhealthy diet, smoking, and lack of physical activity [<a href="#rid18">18</a>]. Individuals with severe mental illness usually have a poor diet that, along with cigarette smoking and lack of exercise, is a major contributor to cardiovascular diseases [<a href="#rid19">19</a>].</p><p>Schizophrenia patients spend an average of 40 percent longer sitting per day, with a 40 percent reduction in physical activity per week compared with healthy controls [<a href="#rid20">20</a>]. Sedentary lifestyle and unhealthy food consumption patterns, including higher daily intake of calories and cholesterol, are common among individuals with major psychotic and/or affective disorders [<a href="#rid21">21</a>].</p><p>Individuals with major psychotic disorders, especially schizophrenia-spectrum disorders, consume more cigarettes per day than do smokers in the general population [<a href="#rid22">22</a>], which partially explains the increased risk of cardiovascular disease in this population. About 25 percent of the general population in the United States are smokers, while up to 75 percent of patients with schizophrenia are smokers [<a href="#rid23">23</a>]. Tobacco users with major psychotic or affective/mood disorders are more likely to consume daily alcohol and caffeine, and less likely to avoid salt and saturated fats [<a href="#rid22">22</a>]. Smokers with schizophrenia reportedly exercise less than nonsmokers [<a href="#rid22">22</a>]. Smoking has been reported to be an independent risk factor for both cardiovascular diseases and diabetes [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H3025103"><span class="h2">Antipsychotic drug side effects</span><span class="headingEndMark"> — </span>Antipsychotic medications, which are first-line treatment for schizophrenia and widely used in other mental disorders [<a href="#rid25">25</a>], have been found to cause weight gain and other metabolic abnormalities. Although second-generation antipsychotics are better tolerated and present with fewer extrapyramidal symptoms compared with first-generation antipsychotics, they are well known to be associated with an increased risk of obesity, impaired glucose tolerance, new-onset diabetes, hyperlipidemia, cardiovascular disease, and metabolic syndrome [<a href="#rid26">26</a>].</p><p>The prevalence of antipsychotic-related metabolic syndrome has been reported in varying samples ranging from 23 to 50 percent.</p><p>Almost all antipsychotics with prolonged use are associated with weight gain to varying degrees [<a href="#rid27">27-33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>High – <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">Clozapine</a> and <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate – <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">Quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10174" href="/d/drug information/10174.html" rel="external">paliperidone</a> <a class="drug drug_general" data-topicid="9087" href="/d/drug information/9087.html" rel="external">iloperidone</a>, sertindole, and zotepine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low – <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">Aripiprazole</a>, amisulpride, <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a>, <a class="drug drug_general" data-topicid="8630" href="/d/drug information/8630.html" rel="external">asenapine</a>, <a class="drug drug_general" data-topicid="102739" href="/d/drug information/102739.html" rel="external">brexpiprazole</a>, <a class="drug drug_general" data-topicid="126411" href="/d/drug information/126411.html" rel="external">lumateperone</a>, <a class="drug drug_general" data-topicid="131761" href="/d/drug information/131761.html" rel="external">olanzapine-samidorphan</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, and most high- to mid-potency first-generation antipsychotics</p><p></p><p>A finding that has been consistent with all antipsychotics that have been studied is that weight gain is greater during treatment of antipsychotic-naïve patients compared with patients with a prior history of antipsychotic use [<a href="#rid30">30</a>].</p><p>Prevention and treatment of antipsychotic-induced metabolic syndrome are reviewed separately, including changes to antipsychotic regimens, lifestyle interventions, smoking cessation, and treatments for individual metabolic abnormalities. (See  <a class="medical medical_review" href="/d/html/117204.html" rel="external">"Approach to managing increased risk for cardiovascular disease in patients with severe mental illness"</a> and  <a class="medical medical_review" href="/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness"</a>.)</p><p class="headingAnchor" id="H3025109"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Target organ damage occurs through multiple mechanisms in metabolic syndrome.</p><p class="headingAnchor" id="H2379352964"><span class="h2">Obesity, insulin resistance, hyperglycemia, and diabetes</span><span class="headingEndMark"> — </span>Excess visceral fat is associated with high insulin resistance [<a href="#rid34">34</a>], which plays an important role in the pathophysiology of metabolic syndrome [<a href="#rid35">35</a>]. The larger expanded adipose tissue leads to an increased turnover of free fatty acids, which are released into the portal circulation and shuttled to the liver, where they are stored as triglyceride (the portal theory of metabolic syndrome) [<a href="#rid34">34,36</a>]. Because of the insulin resistance, insulin itself is unable to properly inhibit lipolysis, leading to an increased flux of free fatty acids being liberated into the plasma circulation [<a href="#rid35">35</a>].</p><p>The hepatic insulin action has been shown to be impaired by the increased flux of free fatty acids [<a href="#rid34">34</a>]. Hepatic insulin resistance and the abundance of free fatty acids lead to an increase in gluconeogenesis that leads to hyperglycemia [<a href="#rid37">37</a>]. Insulin resistance in muscle tissue also results in decreased glucose disposal peripherally [<a href="#rid38">38</a>]. Over time, the pancreatic beta cell continues to decompensate due to the increased need for insulin to overcome resistance, and the result is type 2 diabetes mellitus.</p><p class="headingAnchor" id="H533625326"><span class="h2">Insulin resistance and hypertension</span><span class="headingEndMark"> — </span>The relationship between insulin resistance and hypertension has been well established and it is likely to be multifactorial: partially mediated by endothelial dysfunction caused by free fatty acid-mediated generation of reactive oxygen species, hyperinsulinemia-induced sympathetic nervous system activation and inhibition of nitric oxide synthase, and the effects of adipose tissue-derived cytokines [<a href="#rid34">34,39</a>].</p><p>Hyperactivity of the renin-angiotensin-aldosterone system in seen with obesity [<a href="#rid40">40</a>]. Attention has focused on the role of adipocyte-derived resistin and leptin and their contribution to the pathogenesis of hypertension in patients with insulin resistance [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H2190639810"><span class="h2">Metabolic syndrome and adipokines dysregulation</span><span class="headingEndMark"> — </span>Adipose tissue is an active endocrine organ [<a href="#rid42">42</a>] that secrets bioactive peptides or proteins called adipokines, fundamental to the pathogenesis of the metabolic syndrome. Increased adiposity is associated with overproduction of adipokines with pro-inflammatory properties, while other adipokines with anti-inflammatory or insulin-sensitizing properties are decreased [<a href="#rid43">43</a>].</p><p>Adipokines dysregulation plays a role in obesity-linked metabolic disorders and cardiovascular disease [<a href="#rid43">43</a>]. Deleterious adipokines overproduced in obesity include tumor necrosis factor-alpha, interleukin 6, monocyte chemoattractant protein 1, plasminogen activating factor 1, angiotensinogen, retinol binding protein 4, and adipocyte fatty acid binding protein [<a href="#rid43">43,44</a>].</p><p>Beneficial adipokines dysregulated in obesity include leptin, adiponectin, apelin, resistin, and visfatin [<a href="#rid43">43,45-52</a>].</p><p class="headingAnchor" id="H3025115"><span class="h2">Metabolic syndrome and inflammation</span><span class="headingEndMark"> — </span>Several studies have shown a relationship between obesity, chronic inflammation, and metabolic syndrome [<a href="#rid3">3,53-55</a>]. Metabolic syndrome is associated with an elevated inflammatory state [<a href="#rid56">56</a>]. This is evidenced by the presence of elevated concentrations of inflammatory molecules including C-reactive protein, tumor necrosis factor-alpha, plasma resistin, interleukin 6, and interleukin 18 [<a href="#rid57">57</a>], consistent with the increase in adipose tissue mass characteristic of metabolic syndrome.</p><p>As seen in obesity, levels of the anti-inflammatory adipokine adiponectin are depressed in metabolic syndrome [<a href="#rid58">58</a>]. As the number of metabolic syndrome components an individual exhibits increases, inflammatory markers, including C-reactive protein [<a href="#rid59">59</a>], tumor necrosis factor-alpha [<a href="#rid60">60</a>], interleukin 18 [<a href="#rid61">61</a>], and plasminogen activator inhibitor-1 activity [<a href="#rid62">62</a>] also increase.</p><p>A visceral adipose tissue functions as a paracrine and an endocrine organ, secreting a number of adipokines, some of which are proinflammatory and atherogenic, such as leptin, tumor necrosis factor-alpha, resistin, interleukin 6, and fatty acid-binding protein 4, and others, which have anti-inflammatory, protective effects such as adiponectin [<a href="#rid47">47</a>].</p><p>In metabolic syndrome patients, serum adiponectin levels are decreased, while proinflammatory cytokines are elevated [<a href="#rid3">3</a>]. Dysregulation of adipokines as biomarkers of adipose tissue metabolism plays an essential part in all obesity related diseases [<a href="#rid47">47</a>].</p><p>Adipokine secretion is disturbed by the increased visceral adipose tissue, leading to a low-grade chronic inflammatory state mediated by the infiltration of macrophages into the adipose tissue itself. Macrophages play an important part as the secretory function of adipose tissue and represent the main source of inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin 6. An increase in circulating levels of these inflammatory macrophage-derived factors in obesity leads to a chronic low-grade inflammatory state that has been linked to the development of insulin resistance and type 2 diabetes [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H3025121"><span class="h1">CLINICAL IMPLICATIONS</span></p><p class="headingAnchor" id="H3025129"><span class="h2">Risk of cardiovascular disease</span><span class="headingEndMark"> — </span>Metabolic syndrome is a cluster of individual cardiometabolic risk factors [<a href="#rid64">64</a>], thus a diagnosis of metabolic syndrome would be expected to predict cardiovascular risk [<a href="#rid38">38</a>].</p><p>The vast majority of studies have shown that patients with metabolic syndrome have more cardiovascular disease and are at increased risk for developing cardiovascular disease [<a href="#rid65">65-67</a>]. The presence of metabolic syndrome increases the risk more than is predicted by its component cardiometabolic risk factors when analyzed individually [<a href="#rid68">68</a>].</p><p>The absence of metabolic syndrome does not imply safety from cardiovascular disease. In the Cardiovascular Health Study, cardiovascular disease events occurred in 18 percent of those without a metabolic syndrome diagnosis [<a href="#rid69">69</a>]; the chance of a future myocardial infarction was 23 to 42 percent without a metabolic syndrome diagnosis [<a href="#rid70">70</a>].</p><p>Cardiovascular disease is a major contributor of the increased mortality in subjects with schizophrenia and other severe mental illnesses [<a href="#rid71">71</a>]. Compared with the general population, patients with severe mental illness have nearly twice the risk of dying from cardiovascular disease, especially at an early age [<a href="#rid72">72</a>]. Important causal factors are related to lifestyle, including poor diet, lack of physical activity, smoking, substance misuse, and antipsychotic agents.</p><p class="headingAnchor" id="H3025135"><span class="h2">Risk of type 2 diabetes mellitus</span><span class="headingEndMark"> — </span>Most patients with type 2 diabetes mellitus have insulin resistance and metabolic syndrome before onset of type 2 diabetes mellitus [<a href="#rid73">73,74</a>]. Insulin resistance, hyperinsulinemia, dyslipidemia, and obesity have been shown to precede the progression to type 2 diabetes mellitus in up to 75 to 85 percent of patients [<a href="#rid75">75</a>].</p><p>There is little clinical value in an added diagnosis of metabolic syndrome for risk stratification in patients already diagnosed with type 2 diabetes mellitus [<a href="#rid76">76</a>], confirming other published data that shows that a metabolic syndrome diagnosis does not provide further predictive power for cardiovascular disease events and mortality [<a href="#rid77">77</a>] because type 2 diabetes mellitus is already a cardiovascular disease risk equivalent [<a href="#rid78">78,79</a>].</p><p>All components of the metabolic syndrome definition increase risk of new-onset diabetes when analyzed independently [<a href="#rid80">80</a>]. The more metabolic syndrome components, the higher the risk of type 2 diabetes mellitus [<a href="#rid38">38</a>].</p><p>Of all metabolic syndrome criteria, impaired fasting glucose and impaired glucose tolerance are most strongly associated with diabetes [<a href="#rid81">81,82</a>]. Fasting glucose was a superior predictor of incident diabetes than a diagnosis of metabolic syndrome [<a href="#rid83">83</a>].</p><p>The prevalence of diabetes mellitus is four to five times higher in schizophrenia than in the general population [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H3025141"><span class="h2">Associated conditions</span></p><p class="headingAnchor" id="H3025149"><span class="h3">Nonalcoholic fatty liver disease</span><span class="headingEndMark"> — </span>Metabolic syndrome is associated with nonalcoholic fatty liver disease (NAFLD), which represents the most common cause of chronic liver disease [<a href="#rid84">84</a>]. The prevalence of both metabolic syndrome and NAFLD increases with obesity, excessive intake of simple sugars, and physical inactivity [<a href="#rid85">85</a>].</p><p>Both metabolic syndrome and NAFLD predict type 2 diabetes, cardiovascular disease, nonalcoholic steatohepatitis, and hepatocellular carcinoma [<a href="#rid85">85,86</a>]. (See  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a>.)</p><p>The prevalence of NAFLD increases with the number of metabolic syndrome components present [<a href="#rid87">87</a>]. It has been suggested that 95 percent of obese individuals and up to 70 percent of those with type 2 diabetes mellitus have some form of NAFLD [<a href="#rid88">88</a>]. Although statistical modeling does not support that NAFLD is an independent manifestation that should be added as a component of metabolic syndrome [<a href="#rid87">87</a>], a diagnosis of metabolic syndrome could mean that NAFLD is present; therefore, clinicians should carefully investigate obese patients they suspect might be at risk of developing NAFLD.</p><p>A study of 661,266 subjects in a population based database in Taiwan found that patients with schizophrenia had a significantly higher prevalence and incidence of chronic liver disease compared with those in the general population. Younger patients with schizophrenia had a much higher prevalence and incidence compared with those in the general population. Comorbidity with diabetes was the primary risk factor for patients with schizophrenia to develop chronic liver disease [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H3025155"><span class="h3">Polycystic ovarian syndrome</span><span class="headingEndMark"> — </span>Metabolic syndrome is especially common in obese women with polycystic ovarian syndrome (PCOS) [<a href="#rid90">90</a>]. PCOS presents with anovulation, androgen excess, insulin resistance, fertility problems, and consequences of insulin resistance, such as a significant risk for the development of type 2 diabetes mellitus [<a href="#rid91">91</a>] and cardiovascular disease risk factors [<a href="#rid92">92</a>]. There is, therefore, significant overlap between PCOS and metabolic syndrome. Women with PCOS clearly have a higher prevalence of cardiovascular disease risk factors [<a href="#rid93">93,94</a>]. Although it is not clear whether women with PCOS have a greater risk for cardiovascular disease events, they certainly have evidence of greater risk for subclinical cardiovascular disease [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults"</a>.)</p><p>Studies have found that the prevalence of mental health disorders, such as depression, anxiety, bipolar disorder, and binge eating disorder, is higher in women with PCOS compared with the general population [<a href="#rid96">96,97</a>].</p><p class="headingAnchor" id="H3025161"><span class="h3">Obstructive sleep apnea</span><span class="headingEndMark"> — </span>Obstructive sleep apnea (OSA) is a potentially serious consequence of obesity and is associated with increasing body mass index, insulin resistance [<a href="#rid98">98,99</a>], and inflammation [<a href="#rid100">100</a>], and with reduced adiponectin concentrations [<a href="#rid101">101,102</a>]. Individuals with OSA are more likely to present with the clinical cluster of metabolic syndrome compared with those without OSA [<a href="#rid103">103-105</a>].</p><p>OSA prevalence may be increased in major depressive disorder and posttraumatic stress disorder [<a href="#rid106">106</a>]. There is insufficient evidence of an association between increased OSA and schizophrenia/psychotic disorders, bipolar and related disorders, or anxiety disorders [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H3025167"><span class="h3">Hypogonadism</span><span class="headingEndMark"> — </span>Men with metabolic syndrome appear to have a greater prevalence of hypogonadism [<a href="#rid107">107,108</a>], which is a risk factor for the development of metabolic syndrome and type 2 diabetes mellitus [<a href="#rid109">109</a>]. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p class="headingAnchor" id="H3025173"><span class="h3">Microvascular disease</span><span class="headingEndMark"> — </span>Metabolic syndrome has also been shown to be associated with an increased risk of chronic kidney disease [<a href="#rid110">110</a>], microalbuminuria [<a href="#rid111">111</a>], and neuropathy [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H3025179"><span class="h3">Cancer</span><span class="headingEndMark"> — </span>Other metabolic syndrome-associated diseases can be considered in relation to the component of obesity [<a href="#rid113">113</a>]. Data support the relationship between obesity and the increased risk of colon, pancreas, kidney, prostate, endometrial, and breast cancer [<a href="#rid114">114</a>]. Each individual risk factor for metabolic syndrome also has an association with cancer [<a href="#rid74">74</a>].</p><p>Studies have had conflicting results on whether there is an association between overall cancer incidence/mortality in psychiatric patients compared with the general population [<a href="#rid115">115</a>]. Some have reported an increased risk, other studies no risk, while others have found a lower than expected cancer incidence or mortality; results have varied based on sample, psychiatric diagnosis, cancer site, and methodology [<a href="#rid115">115</a>].</p><p>Patients with psychiatric disorders do not appear more likely to develop cancer compared with the general population, but are more likely to die because of cancer [<a href="#rid115">115</a>]. One reason might be a disparity of care existing among patients with severe mental illness [<a href="#rid116">116</a>]. Cancer care disparities are likely the result of patient-, provider-, and systems-level factors and are influenced by the pervasive stigma of mental illness [<a href="#rid117">117</a>].</p><p class="headingAnchor" id="H1744375867"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Subsequent to the development of multiple, differing criteria for the diagnosis of metabolic syndrome [<a href="#rid4">4,118-120</a>], major clinical and research organizations proposed harmonized criteria defining the syndrome. Diagnosis is based on the presence of any three of the following abnormal findings [<a href="#rid121">121</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting glucose – ≥100 mg/dL (or receiving drug therapy for hyperglycemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure – ≥130/85 mmHg (or receiving drug therapy for hypertension).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Triglycerides – ≥150 mg/dL (or receiving drug therapy for hypertriglyceridemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-density lipoprotein cholesterol – &lt;40 mg/dL in men or &lt;50 mg/dL in women (or receiving drug therapy for reduced high-density lipoprotein cholesterol).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Waist circumference – ≥102 cm (40 in) in men or ≥88 cm (35 in) in women; if Asian American, ≥90 cm (35 in) in men or ≥80 cm (32 in) in women. (The International Diabetes Federation criteria allow the use of a body mass index &gt;30 kg/m<sup>2</sup> in lieu of the waist circumference criterion.)</p><p></p><p class="headingAnchor" id="H928312658"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic syndrome </strong>– Metabolic syndrome is a constellation of risk factors for cardiovascular disease including abdominal obesity, insulin resistance, dyslipidemia (elevated triglycerides levels and low high-density lipoproteins), and hypertension. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The prevalence of metabolic syndrome in the general population ranges between 14 to 18 percent in Europeans and 29 to 32 percent in South Asians. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contributing factors</strong> – Compared with the general population, the prevalence of metabolic syndrome is greater in patients with severe mental illness. Contributing factors include higher rates of a sedentary lifestyle and cigarette smoking, side effects of many antipsychotic medications, and, possibly, the presence of severe mental disorders independent of medication. (See <a class="local">'Contributing factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical implications –</strong> The prevalence of metabolic syndrome is associated with a twofold increase in cardiovascular disease over 5 to 10 years, a fivefold increase in development of diabetes, and an increased risk of mortality. (See <a class="local">'Clinical implications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated conditions</strong> – The diagnosis of metabolic syndrome is associated with other health problems, including fatty liver and chronic liver disease, polycystic ovarian syndrome, hypogonadism, obstructive sleep apnea, microvascular disease, and cancer. (See <a class="local">'Associated conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Major clinical and research organizations have developed consensus-based criteria for the diagnosis of metabolic syndrome based on the presence of at least three abnormalities using specified threshold: fasting glucose, blood pressure, triglycerides, high-density lipoprotein cholesterol, and waist circumference (or body mass index). (See <a class="local">'Diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595.</a></li><li><a class="nounderline abstract_t">Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep 2018; 20:12.</a></li><li><a class="nounderline abstract_t">Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008; 29:777.</a></li><li><a class="nounderline abstract_t">Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735.</a></li><li><a class="nounderline abstract_t">Tillin T, Forouhi N, Johnston DG, et al. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Diabetologia 2005; 48:649.</a></li><li><a class="nounderline abstract_t">Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006; 105:626.</a></li><li><a class="nounderline abstract_t">Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356.</a></li><li><a class="nounderline abstract_t">Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. J Cardiometab Syndr 2007; 2:276.</a></li><li><a class="nounderline abstract_t">Day C. Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 2007; 4:32.</a></li><li><a class="nounderline abstract_t">Khatana SA, Kane J, Taveira TH, et al. Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One 2011; 6:e19298.</a></li><li><a class="nounderline abstract_t">Kilbourne AM, Brar JS, Drayer RA, et al. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007; 48:412.</a></li><li><a class="nounderline abstract_t">Bartoli F, Crocamo C, Caslini M, et al. Schizoaffective disorder and metabolic syndrome: A meta-analytic comparison with schizophrenia and other non-affective psychoses. J Psychiatr Res 2015; 66-67:127.</a></li><li><a class="nounderline abstract_t">Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 2007; 3:495.</a></li><li><a class="nounderline abstract_t">Cohn TA, Remington G, Zipursky RB, et al. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry 2006; 51:382.</a></li><li><a class="nounderline abstract_t">Babić D, Maslov B, Martinac M, et al. Bipolar disorder and metabolic syndrome: comorbidity or side effects of treatment of bipolar disorder. Psychiatr Danub 2010; 22:75.</a></li><li><a class="nounderline abstract_t">Wolkowitz OM, Epel ES, Reus VI, Mellon SH. Depression gets old fast: do stress and depression accelerate cell aging? Depress Anxiety 2010; 27:327.</a></li><li><a class="nounderline abstract_t">Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabet Med 2014; 31:764.</a></li><li><a class="nounderline abstract_t">DE Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10:52.</a></li><li><a class="nounderline abstract_t">Bly MJ, Taylor SF, Dalack G, et al. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord 2014; 16:277.</a></li><li><a class="nounderline abstract_t">Vancampfort D, Probst M, Sweers K, et al. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatr Scand 2011; 123:423.</a></li><li><a class="nounderline abstract_t">Molarius A, Berglund K, Eriksson C, et al. Mental health symptoms in relation to socio-economic conditions and lifestyle factors--a population-based study in Sweden. BMC Public Health 2009; 9:302.</a></li><li><a class="nounderline abstract_t">Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010; 119:101.</a></li><li><a class="nounderline abstract_t">Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115.</a></li><li><a class="nounderline abstract_t">Bergman BC, Perreault L, Hunerdosse D, et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 2012; 61:3156.</a></li><li><a class="nounderline abstract_t">Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008; 69:240.</a></li><li><a class="nounderline abstract_t">Henderson DC, Vincenzi B, Andrea NV, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015; 2:452.</a></li><li><a class="nounderline abstract_t">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.</a></li><li><a class="nounderline abstract_t">Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209.</a></li><li><a class="nounderline abstract_t">Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59:337.</a></li><li><a class="nounderline abstract_t">Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014; 9:e94112.</a></li><li><a class="nounderline abstract_t">Meyer JM, Mao Y, Pikalov A, et al. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol 2015; 30:342.</a></li><li><a class="nounderline abstract_t">Martin WF, Correll CU, Weiden PJ, et al. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. Am J Psychiatry 2019; 176:457.</a></li><li><a class="nounderline abstract_t">Correll CU, Davis RE, Weingart M, et al. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry 2020; 77:349.</a></li><li><a class="nounderline abstract_t">Bergman RN, Kim SP, Hsu IR, et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 2007; 120:S3.</a></li><li><a class="nounderline abstract_t">Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415.</a></li><li><a class="nounderline abstract_t">Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013; 5:1218.</a></li><li><a class="nounderline abstract_t">Nikolic D, Katsiki N, Montalto G, et al. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5:928.</a></li><li><a class="nounderline abstract_t">Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am 2014; 43:1.</a></li><li><a class="nounderline abstract_t">Andreassi MG. Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction. Mutat Res 2009; 667:35.</a></li><li><a class="nounderline abstract_t">Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 2013; 21:8.</a></li><li><a class="nounderline abstract_t">Takata Y, Osawa H, Kurata M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008; 51:534.</a></li><li><a class="nounderline abstract_t">Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548.</a></li><li><a class="nounderline abstract_t">Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314:1.</a></li><li><a class="nounderline abstract_t">Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 2013; 56:10.</a></li><li><a class="nounderline abstract_t">Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 2008; 31:1283.</a></li><li><a class="nounderline abstract_t">Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011; 18:629.</a></li><li><a class="nounderline abstract_t">Kucerova J, Babinska Z, Horska K, Kotolova H. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159:208.</a></li><li><a class="nounderline abstract_t">Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN. Obesity, adipokines and neuroinflammation. Neuropharmacology 2015; 96:124.</a></li><li><a class="nounderline abstract_t">Baskin DG, Figlewicz Lattemann D, Seeley RJ, et al. Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res 1999; 848:114.</a></li><li><a class="nounderline abstract_t">Kong AP, Chan NN, Chan JC. The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr Diabetes Rev 2006; 2:397.</a></li><li><a class="nounderline abstract_t">Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307.</a></li><li><a class="nounderline abstract_t">Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 2006; 1:e31.</a></li><li><a class="nounderline abstract_t">Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860.</a></li><li><a class="nounderline abstract_t">Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010; 2010.</a></li><li><a class="nounderline abstract_t">Klöting N, Blüher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord 2014; 15:277.</a></li><li><a class="nounderline abstract_t">Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord 2004; 2:82.</a></li><li><a class="nounderline abstract_t">Norata GD, Ongari M, Garlaschelli K, et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156:279.</a></li><li><a class="nounderline abstract_t">Bahia L, Aguiar LG, Villela N, et al. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics (Sao Paulo) 2006; 61:433.</a></li><li><a class="nounderline abstract_t">González AS, Guerrero DB, Soto MB, et al. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006; 60:802.</a></li><li><a class="nounderline abstract_t">Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004; 89:2697.</a></li><li><a class="nounderline abstract_t">Hung J, McQuillan BM, Chapman CM, et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25:1268.</a></li><li><a class="nounderline abstract_t">Mertens I, Verrijken A, Michiels JJ, et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30:1308.</a></li><li><a class="nounderline abstract_t">Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316:129.</a></li><li><a class="nounderline abstract_t">Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007; 115:1806.</a></li><li><a class="nounderline abstract_t">Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164:1066.</a></li><li><a class="nounderline abstract_t">Jeppesen J, Hansen TW, Rasmussen S, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007; 49:2112.</a></li><li><a class="nounderline abstract_t">Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709.</a></li><li><a class="nounderline abstract_t">Eberly LE, Prineas R, Cohen JD, et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29:123.</a></li><li><a class="nounderline abstract_t">Scuteri A, Najjar SS, Morrell CH, et al. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005; 28:882.</a></li><li><a class="nounderline abstract_t">Eddy DM, Schlessinger L, Heikes K. The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes (Lond) 2008; 32 Suppl 2:S5.</a></li><li><a class="nounderline abstract_t">Wootton RE, Richmond RC, Stuijfzand BG, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychol Med 2020; 50:2435.</a></li><li><a class="nounderline abstract_t">De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006; 21 Suppl 2:S11.</a></li><li><a class="nounderline abstract_t">Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25:391.</a></li><li><a class="nounderline abstract_t">O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 2015; 16:1.</a></li><li><a class="nounderline abstract_t">Lebovitz HE. Type 2 diabetes: an overview. Clin Chem 1999; 45:1339.</a></li><li><a class="nounderline abstract_t">Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007; 116:2119.</a></li><li><a class="nounderline abstract_t">Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27:2689.</a></li><li><a class="nounderline abstract_t">Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48:1684.</a></li><li><a class="nounderline abstract_t">Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48:937.</a></li><li><a class="nounderline abstract_t">Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371:1927.</a></li><li><a class="nounderline abstract_t">Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31:1898.</a></li><li><a class="nounderline abstract_t">Ford ES, Schulze MB, Pischon T, et al. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol 2008; 7:35.</a></li><li><a class="nounderline abstract_t">Cameron AJ, Magliano DJ, Zimmet PZ, et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 2008; 264:177.</a></li><li><a class="nounderline abstract_t">Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24:695.</a></li><li><a class="nounderline abstract_t">Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2:901.</a></li><li><a class="nounderline abstract_t">Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51:1820.</a></li><li><a class="nounderline abstract_t">Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 2013; 28:664.</a></li><li><a class="nounderline abstract_t">Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005; 28:1518.</a></li><li><a class="nounderline abstract_t">Hsu JH, Chien IC, Lin CH, et al. Increased risk of chronic liver disease in patients with schizophrenia: a population-based cohort study. Psychosomatics 2014; 55:163.</a></li><li><a class="nounderline abstract_t">Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48.</a></li><li><a class="nounderline abstract_t">Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.</a></li><li><a class="nounderline abstract_t">Cho LW, Atkin SL. Cardiovascular risk in women with polycystic ovary syndrome. Minerva Endocrinol 2007; 32:263.</a></li><li><a class="nounderline abstract_t">Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004; 89:3696.</a></li><li><a class="nounderline abstract_t">Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20:2414.</a></li><li><a class="nounderline abstract_t">Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:2562.</a></li><li><a class="nounderline abstract_t">Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6:1.</a></li><li><a class="nounderline abstract_t">Krępuła K, Bidzińska-Speichert B, Lenarcik A, Tworowska-Bardzińska U. Psychiatric disorders related to polycystic ovary syndrome. Endokrynol Pol 2012; 63:488.</a></li><li><a class="nounderline abstract_t">Punjabi NM, Sorkin JD, Katzel LI, et al. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002; 165:677.</a></li><li><a class="nounderline abstract_t">Tasali E, Van Cauter E. Sleep-disordered breathing and the current epidemic of obesity: consequence or contributing factor? Am J Respir Crit Care Med 2002; 165:562.</a></li><li><a class="nounderline abstract_t">Peled N, Kassirer M, Shitrit D, et al. The association of OSA with insulin resistance, inflammation and metabolic syndrome. Respir Med 2007; 101:1696.</a></li><li><a class="nounderline abstract_t">Masserini B, Morpurgo PS, Donadio F, et al. Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest 2006; 29:700.</a></li><li><a class="nounderline abstract_t">Zhang XL, Yin KS, Wang H, Su S. Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration 2006; 73:73.</a></li><li><a class="nounderline abstract_t">Gami AS, Somers VK. Obstructive sleep apnoea, metabolic syndrome, and cardiovascular outcomes. Eur Heart J 2004; 25:709.</a></li><li><a class="nounderline abstract_t">Gruber A, Horwood F, Sithole J, et al. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 5:22.</a></li><li><a class="nounderline abstract_t">Parish JM, Adam T, Facchiano L. Relationship of metabolic syndrome and obstructive sleep apnea. J Clin Sleep Med 2007; 3:467.</a></li><li><a class="nounderline abstract_t">Gupta MA, Simpson FC. Obstructive sleep apnea and psychiatric disorders: a systematic review. J Clin Sleep Med 2015; 11:165.</a></li><li><a class="nounderline abstract_t">Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab 2006; 8:429.</a></li><li><a class="nounderline abstract_t">Corona G, Mannucci E, Petrone L, et al. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007; 4:1038.</a></li><li><a class="nounderline abstract_t">Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14:226.</a></li><li><a class="nounderline abstract_t">Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol 2007; 2:976.</a></li><li><a class="nounderline abstract_t">Klausen KP, Parving HH, Scharling H, Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 2007; 262:470.</a></li><li><a class="nounderline abstract_t">Gordon Smith A, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci 2006; 242:9.</a></li><li><a class="nounderline abstract_t">Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.</a></li><li><a class="nounderline abstract_t">Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med 2013; 64:45.</a></li><li><a class="nounderline abstract_t">Kisely S, Forsyth S, Lawrence D. Why do psychiatric patients have higher cancer mortality rates when cancer incidence is the same or lower? Aust N Z J Psychiatry 2016; 50:254.</a></li><li><a class="nounderline abstract_t">Moore S, Shiers D, Daly B, et al. Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Acta Psychiatr Scand 2015; 132:109.</a></li><li><a class="nounderline abstract_t">Irwin KE, Henderson DC, Knight HP, Pirl WF. Cancer care for individuals with schizophrenia. Cancer 2014; 120:323.</a></li><li><a class="nounderline abstract_t">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.</a></li><li><a class="nounderline abstract_t">Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469.</a></li><li><a class="nounderline abstract_t">Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366:1059.</a></li><li><a class="nounderline abstract_t">Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640.</a></li></ol></div><div id="topicVersionRevision">Topic 14775 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3056758" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Banting lecture 1988. Role of insulin resistance in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29480368" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Global Epidemic of the Metabolic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971485" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157765" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15759110" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16935763" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of obesity and metabolic syndrome in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790215" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18059211" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The metabolic syndrome in East Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469041" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Metabolic syndrome, or What you will: definitions and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21541294" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878500" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26004300" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Schizoaffective disorder and metabolic syndrome: A meta-analytic comparison with schizophrenia and other non-affective psychoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300578" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fifty years chlorpromazine: a historical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16786820" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305595" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bipolar disorder and metabolic syndrome: comorbidity or side effects of treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20376837" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Depression gets old fast: do stress and depression accelerate cell aging?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24606397" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21379357" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330321" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21219266" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19695085" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mental health symptoms in relation to socio-economic conditions and lifestyle factors--a population-based study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219322" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16338246" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Schizophrenia and increased risks of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22966072" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Novel and reversible mechanisms of smoking-induced insulin resistance in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363452" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26360288" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747245" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Consensus development conference on antipsychotic drugs and obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172203" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11926934" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763306" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Almost all antipsychotics result in weight gain: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196189" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30845818" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31913424" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296343" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15836891" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23584084" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dyslipidemia in obesity: mechanisms and potential targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23507795" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24582089" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19028510" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401272" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180399" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181022" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adipose tissue as an endocrine organ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682539" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23052058" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18957797" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The metabolic syndrome as a concept of adipose tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737960" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25485531" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25582291" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Obesity, adipokines and neuroinflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10612703" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18220644" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11201732" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The hormone resistin links obesity to diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17183659" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17167474" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Inflammation and metabolic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20706689" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chronic inflammation in obesity and the metabolic syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25344447" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adipocyte dysfunction, inflammation and metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18370640" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The metabolic syndrome and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287419" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Plasma resistin levels correlate with determinants of the metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17072441" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16493453" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181044" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15790931" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16389265" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19723556" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Adipose tissue as an endocrine organ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404171" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Metabolic syndrome: is it a syndrome? Does it matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159263" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531661" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460094" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16373907" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793190" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18469838" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The metabolic syndrome and cardiovascular risk: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31689377" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601508" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16011472" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The insulin resistance syndrome: definition and dietary approaches to treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25407540" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430816" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Type 2 diabetes: an overview</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17967769" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505006" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079964" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10331395" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hyperglycemia and cardiovascular disease in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501419" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591398" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Metabolic syndrome and incident diabetes: current state of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077281" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18298479" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955971" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24731669" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20432259" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23286209" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920084" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932529" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Increased risk of chronic liver disease in patients with schizophrenia: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249284" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333916" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18091663" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cardiovascular risk in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292291" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073846" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788855" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24379699" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Epidemiology, diagnosis, and management of polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23339008" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Psychiatric disorders related to polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874813" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Sleep-disordered breathing and insulin resistance in middle-aged and overweight men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874803" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Sleep-disordered breathing and the current epidemic of obesity: consequence or contributing factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466499" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The association of OSA with insulin resistance, inflammation and metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17033258" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Reduced levels of adiponectin in sleep apnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16205042" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120876" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Obstructive sleep apnoea, metabolic syndrome, and cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17078884" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17803009" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Relationship of metabolic syndrome and obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406268" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Obstructive sleep apnea and psychiatric disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776750" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Relative androgen deficiency in relation to obesity and metabolic status in older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17627748" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940444" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Androgen deficiency, diabetes, and the metabolic syndrome in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702729" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875184" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16448668" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Idiopathic neuropathy, prediabetes and the metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711737" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121183" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25829481" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Why do psychiatric patients have higher cancer mortality rates when cancer incidence is the same or lower?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25958971" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24151022" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cancer care for individuals with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12485966" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681555" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182882" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The metabolic syndrome--a new worldwide definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805654" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
